Description du projet
Un analgésique innovant à base de composés marins pour la douleur chronique
La douleur chronique touche 100 millions de personnes rien qu’en Europe, ce qui en fait l’une des principales causes d’invalidité, avec de profondes répercussions sur la qualité de vie. Bien que très efficaces pour traiter la douleur, les médicaments opioïdes posent un risque de dépendance et d’autres effets secondaires nocifs. La société de biotechnologie Sea4Us a développé Sea4Pain, un médicament révolutionnaire dérivé de composés marins. Sea4Pain a le potentiel d’alléger les souffrances de milliards de personnes dans le monde. Le projet Sea4Market, financé par le CEI, ambitionne de valider cliniquement Sea4Pain par le biais d’essais chez l’humain et d’obtenir ensuite une licence pour la technologie afin de rapidement s’implanter sur le marché de la douleur chronique, qui pèse plusieurs milliards d’euros. Le soutien du CEI est crucial pour la réussite de cette initiative à haut risque mais très prometteuse.
Objectif
Sea4Us is a world-class biotechnology company with a focus on translating marine-derived compounds with therapeutic potential for unmet medical needs into pharmaceutical assets. Sea4Us has developed a platform focused on drug discovery and development of novel pharmaceuticals based on its core expertise in ion channels and marine biology. Sea4Us is particularly focussed on developing and commercialising therapies for chronic pain.
Sea4Us has developed a ground-breaking therapeutic drug to treat chronic pain in patients. Chronic pain affects 100 million people across Europe, 1.6bn globally, and has a devastating impact on quality of life. Pain is the most common reason people visit their doctors and a leading cause of disability. It is a source of enormous social and economic burden, costing Europe alone over 500 billion Euros a year. There are many medications on the market for treating chronic pain, but they are either ineffective for most types of chronic pain and/or have adverse side-effects. Opioid drugs are the most effective treatment but also inflict drug addiction, habituation and other noxious side-effects. Our novel analgesic molecule, Sea4Pain, has a novel mechanism of action meaning it is highly effective at treating chronic pain and without any known side effects unlike current drugs on the market. Sea4Pain is a first-in-class drug and has the potential to ease the suffering of billions of people globally.
This EIC Accelerator project, called Sea4Market, will enable us to clinically validate our novel analgesic through completion of First-in-Human trials and out-license our technology to make a rapid entry into the multi-billion Euro Chronic Pain market. EIC support is essential to deliver this high-risk, high reward project and will enable the sustainable growth of our business. We will re-invest revenues from our licencing deal back into our project pipeline to solve other unmet medical needs and ensure the sustainable growth of our company.
Champ scientifique
Mots‑clés
Programme(s)
- HORIZON.3.1 - The European Innovation Council (EIC) Main Programme
Régime de financement
HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended FinanceCoordinateur
8650-368 SAGRES
Portugal
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.